DK3749334T3 - Allogen hæmatopoietisk stamcelletransplantation - Google Patents

Allogen hæmatopoietisk stamcelletransplantation Download PDF

Info

Publication number
DK3749334T3
DK3749334T3 DK19750722.1T DK19750722T DK3749334T3 DK 3749334 T3 DK3749334 T3 DK 3749334T3 DK 19750722 T DK19750722 T DK 19750722T DK 3749334 T3 DK3749334 T3 DK 3749334T3
Authority
DK
Denmark
Prior art keywords
stem cell
hematopoietic stem
cell transplantation
allogenic hematopoietic
allogenic
Prior art date
Application number
DK19750722.1T
Other languages
Danish (da)
English (en)
Inventor
Everett Hurteau Meyer
Robert S Negrin
Original Assignee
Univ Leland Stanford Junior
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Leland Stanford Junior filed Critical Univ Leland Stanford Junior
Application granted granted Critical
Publication of DK3749334T3 publication Critical patent/DK3749334T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0647—Haematopoietic stem cells; Uncommitted or multipotent progenitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/001—Preparations to induce tolerance to non-self, e.g. prior to transplantation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/22—Immunosuppressive or immunotolerising
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/418—Antigens related to induction of tolerance to non-self
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0637—Immunosuppressive T lymphocytes, e.g. regulatory T cells or Treg
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/122—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells for inducing tolerance or supression of immune responses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/11—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from blood or immune system cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Transplantation (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK19750722.1T 2018-02-08 2019-02-07 Allogen hæmatopoietisk stamcelletransplantation DK3749334T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862628015P 2018-02-08 2018-02-08
PCT/US2019/017017 WO2019157158A2 (en) 2018-02-08 2019-02-07 Methods for allogenic hematopoietic stem cell transplantation

Publications (1)

Publication Number Publication Date
DK3749334T3 true DK3749334T3 (da) 2025-02-17

Family

ID=67549051

Family Applications (1)

Application Number Title Priority Date Filing Date
DK19750722.1T DK3749334T3 (da) 2018-02-08 2019-02-07 Allogen hæmatopoietisk stamcelletransplantation

Country Status (10)

Country Link
US (5) US11952588B2 (cg-RX-API-DMAC7.html)
EP (2) EP4529957A3 (cg-RX-API-DMAC7.html)
JP (2) JP7422667B2 (cg-RX-API-DMAC7.html)
CN (1) CN111971052B (cg-RX-API-DMAC7.html)
AU (2) AU2019218792A1 (cg-RX-API-DMAC7.html)
CA (1) CA3090175A1 (cg-RX-API-DMAC7.html)
DK (1) DK3749334T3 (cg-RX-API-DMAC7.html)
ES (1) ES3012854T3 (cg-RX-API-DMAC7.html)
PL (1) PL3749334T3 (cg-RX-API-DMAC7.html)
WO (1) WO2019157158A2 (cg-RX-API-DMAC7.html)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES3012854T3 (en) 2018-02-08 2025-04-10 Univ Leland Stanford Junior Allogenic hematopoietic stem cell transplantation
US12492254B2 (en) 2018-02-23 2025-12-09 H. Lee Moffitt Cancer Center and Research Intitute. Inc. CD83-binding chimeric antigen receptors
EP4013447A4 (en) * 2019-08-16 2024-05-29 H. Lee Moffitt Cancer Center & Research Institute, Inc. T CELLS EXPRESSING A CHIMERIC ANTI-CD83 ANTIGEN RECEPTOR
CN117177748A (zh) * 2020-11-04 2023-12-05 浩康生物系统公司 用于异基因造血干细胞移植的方法
AU2021373797A1 (en) * 2020-11-04 2023-06-08 Orca Biosystems, Inc. Methods for allogeneic hematopoietic stem cell transplantation
WO2022204523A1 (en) * 2021-03-25 2022-09-29 Cellenkos, Inc. Populations of enriched regulatory t cells and methods for producing same
EP4426318A4 (en) * 2021-11-04 2025-11-19 Orca Biosystems Inc THERAPEUTIC COMPOSITIONS AND TRANSPLANTATION PROCESSES OF ALLOGENEIC HEMATOPOIETIC CELLS
AU2023252879A1 (en) * 2022-04-15 2024-11-21 Orca Biosystems, Inc. Methods for allogeneic hematopoietic stem cell transplantation
EP4611778A4 (en) * 2022-11-03 2026-07-15 Orca Biosystems Inc COMPOSITION AND METHODS FOR HEMATOPOIETIC STEM CELL TRANSPLANTS
CN121693336A (zh) * 2023-05-09 2026-03-17 麦克莱恩医院公司 帕金森病细胞疗法中自体treg和mda细胞的纹状体内共移植

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL107483A0 (en) 1993-11-03 1994-02-27 Yeda Res & Dev Bone marrow transplantation
EP1461087A1 (en) * 2001-12-06 2004-09-29 Institut National De La Sante Et De La Recherche Medicale (Inserm) Use of cd34+ hematopoietic progenitor cells for the treatment of cns disorders
JP4988172B2 (ja) 2005-06-24 2012-08-01 株式会社日立製作所 固体酸化物形燃料電池発電システム
EP2514315A3 (en) 2005-08-24 2012-11-07 Yeda Research and Development Co. Ltd. Universal donor-derived tolerogenic cells for inducing non-syngeneic transplantation tolerance
US11291686B2 (en) 2008-05-30 2022-04-05 University Of Louisville Research Foundation, Inc. Human facilitating cells
US8632768B2 (en) 2008-05-30 2014-01-21 University Of Louisville Research Foundation, Inc. Human facilitating cells
WO2010022341A1 (en) 2008-08-21 2010-02-25 The United State Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of enriching and using regulatory t cells
US8772028B2 (en) 2008-11-07 2014-07-08 Sunnybrook Health Sciences Centre CD34+CD7+CD5+CD1a-human progenitor T-cells produced in vitro and methods of using
AU2010278702C1 (en) * 2009-07-31 2016-07-14 Forsyth Dental Infirmary For Children Programming of cells for tolerogenic therapies
EP2378287A1 (en) 2010-04-15 2011-10-19 TXCell New method for isolating Tr1 cells
RU2657758C2 (ru) 2011-12-22 2018-06-15 Иеда Рисеч Энд Девелопмент Ко. Лтд. Комбинированная терапия для стабильного и долговременного приживления трансплантата
WO2013130499A1 (en) 2012-02-29 2013-09-06 University Of Virginia Patent Foundation Compositions and methods for cxcr4 signaling and umbilical cord blood stem cell engraftment
WO2013173076A1 (en) 2012-05-04 2013-11-21 University Of Southern California Methods and compositions for generating and using allogeneic suppressor cells
WO2014165581A1 (en) 2013-04-02 2014-10-09 New York University Gpr15-mediated homing and uses thereof
US11850592B2 (en) 2017-11-13 2023-12-26 Owl biomedical, Inc. Particle manipulation system with multisort valve
US20160250258A1 (en) * 2013-10-31 2016-09-01 Fred Hutchinson Cancer Research Center Modified hematopoietic stem/progenitor and non-t effector cells, and uses thereof
WO2015171691A2 (en) 2014-05-06 2015-11-12 Scholar Rock, Inc. Compositions and methods for growth factor modulation
RU2751362C2 (ru) 2014-12-29 2021-07-13 Новартис Аг Способы получения экспрессирующих химерный антигенный рецептор клеток
PL3265123T3 (pl) 2015-03-03 2023-03-13 Kymab Limited Przeciwciała, zastosowania i sposoby
WO2017023753A1 (en) 2015-07-31 2017-02-09 University Of Florida Research Foundation, Inc. Hematopoietic stem cells in combinatorial therapy with immune checkpoint inhibitors against cancer
JP7105188B2 (ja) 2015-08-25 2022-07-22 ザ・ユー・エイ・ビー・リサーチ・フアンデーシヨン 幹細胞移植方法
US20180251731A1 (en) 2015-09-07 2018-09-06 INSERM (Institute National de la Santé et de la Recherche Médicale) Subpopulation of cd8+cd45rclow tregs and uses thereof
KR20180086204A (ko) 2015-11-05 2018-07-30 글리코스템 떼라퓨틱스 비.브이. 면역치료법에 사용하기 위한 조성물
US20190032013A1 (en) 2016-01-29 2019-01-31 Tract Therapeutics, Inc. Immune cell selection, expansion, and use
US10383895B2 (en) 2016-02-18 2019-08-20 Viera Bioscience, Inc. Stimulation of therapeutic angiogenesis by T regulatory cells
EP3430052A2 (en) 2016-03-14 2019-01-23 Millennium Pharmaceuticals, Inc. Method of preventing graft versus host disease
WO2018106610A1 (en) 2016-12-05 2018-06-14 The Regents Of The University Of California Immunomagnetic bead-based method to enrich stem cells from whole hematopoietic tissue
CN110913690A (zh) 2017-03-14 2020-03-24 朱诺治疗学股份有限公司 用于低温储存的方法
CN118662615A (zh) 2017-03-15 2024-09-20 浩康生物系统公司 用于造血干细胞移植的组合物和方法
US11662343B2 (en) 2017-04-07 2023-05-30 The Council Of The Queensland Institute Of Medical Research Cellular populations and uses thereof
EP3450981A1 (en) 2017-08-28 2019-03-06 Trizell GmbH Btnl8 as a marker for tregs
ES3012854T3 (en) 2018-02-08 2025-04-10 Univ Leland Stanford Junior Allogenic hematopoietic stem cell transplantation
EP3765044A4 (en) 2018-03-12 2021-12-08 Medeor Therapeutics, Inc. TREATMENT METHODS FOR NON-CANCERIOUS DISORDERS USING HEMATOPOIETIC CELLS
US10881692B2 (en) 2018-04-05 2021-01-05 Medeor Therapeutics, Inc. Compositions for establishing mixed chimerism and methods of manufacture thereof
US10842821B2 (en) 2018-04-05 2020-11-24 Medeor Therapeutics, Inc. Cellular compositions derived from prior organ donors and methods of manufacture and use thereof
US20220305057A1 (en) 2019-06-06 2022-09-29 Medeor Therapeutics, Inc. Methods of making cellular products by post- mortem mobilization and harvesting of hematopoietic cells
AU2021373797A1 (en) 2020-11-04 2023-06-08 Orca Biosystems, Inc. Methods for allogeneic hematopoietic stem cell transplantation

Also Published As

Publication number Publication date
JP2021512903A (ja) 2021-05-20
EP3749334A4 (en) 2021-11-17
US20240344027A1 (en) 2024-10-17
ES3012854T3 (en) 2025-04-10
US20220380729A1 (en) 2022-12-01
CA3090175A1 (en) 2019-08-15
US11447747B2 (en) 2022-09-20
AU2019218792A1 (en) 2020-09-03
US20210015862A1 (en) 2021-01-21
JP2024041938A (ja) 2024-03-27
WO2019157158A2 (en) 2019-08-15
EP4529957A3 (en) 2025-04-30
EP3749334B1 (en) 2024-12-11
WO2019157158A3 (en) 2020-04-30
US11952588B2 (en) 2024-04-09
PL3749334T3 (pl) 2025-04-07
JP7652949B2 (ja) 2025-03-27
CN111971052B (zh) 2024-07-05
CN111971052A (zh) 2020-11-20
EP3749334A2 (en) 2020-12-16
AU2025271013A1 (en) 2025-12-11
US20210030797A1 (en) 2021-02-04
US20210002613A1 (en) 2021-01-07
EP4529957A2 (en) 2025-04-02
JP7422667B2 (ja) 2024-01-26

Similar Documents

Publication Publication Date Title
IL285580A (en) Cryopreservation of stem cells
IL281113A (en) Genetically engineered hematopoietic stem cells and uses thereof
PL3749334T3 (pl) Allogeniczne przeszczepienie krwiotwórczych komórek macierzystych
NO2025012I1 (no) Autologous anti-CD19-transduced CD3+ cells (brexucabtagene autoleucel)
IL271441A (en) Flow cells
EP3455344A4 (en) Hematopoietic stem / precursor cells
IL282637A (en) Methods for allogeneic transplantation of hematopoietic stem cells
IL283607A (en) Immunotherapies using enhanced ipsc derived effector cells
EP4021180A4 (en) CELL CRYOPRESERVATION MEDIUM
IL269203A (en) Compositions and methods for selective elimination and replacement of hematopoietic stem cells
IL289124A (en) Flow cells
EP3510145A4 (en) IMMUNCELLS FROM INDUCED PLURIPOTENT STEM CELLS
DE102019100477A8 (de) Sram-speicher
EP3440726A4 (en) LITHIUM ION CELLS AND ANODES THEREFOR
IL285083A (en) Culture media for pluripotent stem cells
EP3448982A4 (en) CELL CULTURE MEDIUM
EP3538115A4 (en) STEM CELL-DERIVED SWAN CELLS
HUE054615T2 (hu) Kompozíció alkalmazásra hematopoetikus õssejtek átoltási hatékonyságának növelésében transzplantáció után
EP3647407A4 (en) CELL CULTURE DEVICE
KR102318115B9 (ko) 세포 대량배양 시스템
EP3655523C0 (en) CELL CULTURE MATERIALS
IL260858B (en) Mesenchymal stem cells as vaccine adjuvants and methods for using the same
DK3436568T3 (da) Kulturmedium til pluripotente stamceller
EP3615044A4 (en) THERAPEUTIC FORMULAS CONTAINING CD34 + STEM CELLS DERIVED FROM NEGATIVE SELECTION
IL284066A (en) Flow cells